New pill could ease stiffness and pain for ankylosing spondylitis patients
NCT ID NCT05861102
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests an oral drug called jaktinib in 265 adults with active ankylosing spondylitis, a type of arthritis that mainly affects the spine. Participants take either jaktinib or a placebo twice daily for 16 weeks. The main goal is to see if jaktinib can reduce pain and improve function by at least 40% compared to placebo.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Jaktinib (an oral drug that targets inflammation)
What this could lead to
If successful, jaktinib could offer a new daily pill to control symptoms and slow disease progression for people with ankylosing spondylitis.
What could go wrong
This is a relatively small Phase 3 trial, and results may not apply to all patients. Jaktinib may cause side effects like infection risk, and it requires ongoing daily use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANKYLOSING SPONDYLITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
RenJi Hospital
Shanghai, Shanghai Municipality, 200001, China